These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31020489)

  • 1. Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
    Macieja A; Kopa P; Galita G; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2019 Aug; 46(4):3625-3636. PubMed ID: 31020489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
    Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
    Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
    Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
    Pastwa E; Poplawski T; Lewandowska U; Somiari SB; Blasiak J; Somiari RI
    Int J Biochem Cell Biol; 2014 Aug; 53():423-31. PubMed ID: 24953561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
    Willmore E; de Caux S; Sunter NJ; Tilby MJ; Jackson GH; Austin CA; Durkacz BW
    Blood; 2004 Jun; 103(12):4659-65. PubMed ID: 15010369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
    Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
    Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
    Stachelek GC; Peterson-Roth E; Liu Y; Fernandez RJ; Pike LR; Qian JM; Abriola L; Hoyer D; Hungerford W; Merkel J; Glazer PM
    Mol Cancer Res; 2015 Oct; 13(10):1389-97. PubMed ID: 26116172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
    Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
    Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining.
    Bergs JW; Krawczyk PM; Borovski T; ten Cate R; Rodermond HM; Stap J; Medema JP; Haveman J; Essers J; van Bree C; Stalpers LJ; Kanaar R; Aten JA; Franken NA
    DNA Repair (Amst); 2013 Jan; 12(1):38-45. PubMed ID: 23237939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.
    Frankenberg-Schwager M; Becker M; Garg I; Pralle E; Wolf H; Frankenberg D
    Radiat Res; 2008 Dec; 170(6):784-93. PubMed ID: 19138034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions.
    Macieja A; Gulbas I; Popławski T
    Curr Issues Mol Biol; 2023 Sep; 45(10):7915-7932. PubMed ID: 37886943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
    Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
    Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human polynucleotide kinase participates in repair of DNA double-strand breaks by nonhomologous end joining but not homologous recombination.
    Karimi-Busheri F; Rasouli-Nia A; Allalunis-Turner J; Weinfeld M
    Cancer Res; 2007 Jul; 67(14):6619-25. PubMed ID: 17638872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
    Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
    Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.
    Poplawski T; Blasiak J
    Mol Biol Rep; 2010 Jun; 37(5):2309-15. PubMed ID: 19697154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
    Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
    Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
    Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
    DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A DNA repair player, ring finger protein 43, relieves etoposide-induced topoisomerase II poisoning.
    Lerksuthirat T; Wikiniyadhanee R; Stitchantrakul W; Chitphuk S; Stansook N; Pipatpanyanugoon N; Jirawatnotai S; Dejsuphong D
    Genes Cells; 2020 Nov; 25(11):718-729. PubMed ID: 32939879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.